These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 24156179)

  • 1. Life-threatening hyperkalemia: a potentially lethal drug combination.
    Juvet T; Gourineni VC; Ravi S; Zarich SW
    Conn Med; 2013 Sep; 77(8):491-3. PubMed ID: 24156179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin-converting enzyme inhibitor and spironolactone.
    Erden I; Yalcin S; Ozhan H
    Kardiol Pol; 2010 Sep; 68(9):1043-5; discussion 1046. PubMed ID: 20859899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [An elderly man with known heart failure admitted with cardiogenic shock].
    Hovland A; Fagerheim AK; Hardersen R; Nielsen EW
    Tidsskr Nor Laegeforen; 2010 Jul; 130(13):1352-4. PubMed ID: 20596117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Life threatening hyperkalemia chronic kidney diseases patients treated with trimethoprim-sulfamethoxazole: a case series.
    Calderón-Ortiz R; Colton-Verge P; Muñiz-Ortega M; Lespier L; Córdova H
    Bol Asoc Med P R; 2011; 103(3):15-7. PubMed ID: 23210327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperkalemia and trimethoprim-sulfamethoxazole: a new problem emerges 25 years later.
    Perazella MA
    Conn Med; 1997 Aug; 61(8):451-8. PubMed ID: 9309892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life-threatening, preventable hyperkalemia in a nursing home resident: case report and literature review.
    Dharmarajan TS; Nguyen T; Russell RO
    J Am Med Dir Assoc; 2005; 6(6):400-5. PubMed ID: 16286062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life-threatening hyperkalemia during a combined therapy with the angiotensin receptor blocker candesartan and spironolactone.
    Fujii H; Nakahama H; Yoshihara F; Nakamura S; Inenaga T; Kawano Y
    Kobe J Med Sci; 2005; 51(1-2):1-6. PubMed ID: 16199929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trimethoprim-sulfamethoxazole: hyperkalemia is an important complication regardless of dose.
    Perazella MA; Mahnensmith RL
    Clin Nephrol; 1996 Sep; 46(3):187-92. PubMed ID: 8879854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arrhythmias and ECG changes in life threatening hyperkalemia in older patients treated by potassium sparing drugs.
    Berkova M; Berka Z; Topinkova E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):84-91. PubMed ID: 23128820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Life threatening hyperkalemia and acidosis secondary to trimethoprim-sulfamethoxazole treatment.
    Margassery S; Bastani B
    J Nephrol; 2001; 14(5):410-4. PubMed ID: 11730276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Late drug-induced hyperkalemia in a patient with congestive heart failure].
    Konopa J; Bułło B; Rutkowski B
    Przegl Lek; 2005; 62(7):732-3. PubMed ID: 16463712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Electrocardiogram changes in hyperkalemia: there and back again.
    Zimlichman E; Liran O
    Isr Med Assoc J; 2005 Nov; 7(11):748. PubMed ID: 16309005
    [No Abstract]   [Full Text] [Related]  

  • 15. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases.
    Schepkens H; Vanholder R; Billiouw JM; Lameire N
    Am J Med; 2001 Apr; 110(6):438-41. PubMed ID: 11331054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Life threatening hyperkalemia: the value of the electrocardiogram].
    Trof RJ; Brouwer RM
    Ned Tijdschr Geneeskd; 2004 May; 148(20):969-75. PubMed ID: 15181720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A patient with severe hyperkalaemia -- an emergency after RALES].
    Nürnberger J; Daul A; Philipp T
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2008-11. PubMed ID: 16143930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in diagnosis and management of hypokalemic and hyperkalemic emergencies.
    Pepin J; Shields C
    Emerg Med Pract; 2012 Feb; 14(2):1-17; quiz 17-8. PubMed ID: 22413702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Automatic detection of spironolactone - related adverse drug events.
    Huang C; Noirot LA; Reichley RM; Bouselli DA; Dunagan WC; Bailey TC
    AMIA Annu Symp Proc; 2005; 2005():989. PubMed ID: 16779276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.